Abbott Laboratories vs Core Scientific Inc — how do they compare? Abbott Laboratories trades at $110.91 (market cap $187.95B), while Core Scientific Inc trades at $20.9 (market cap $6.35B). The key difference: Abbott Laboratories is far larger — about 29.6× Core Scientific Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals.
| ABT | CORZ | |
|---|---|---|
Market Cap | $187.95B | $6.35B |
Sector | Health | Technology |
52-Week High | $136.62 | $29.16 |
52-Week Low | $82.57 | $13.55 |
Enterprise Value | $214.96B | $8.88B |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Core Scientific (CORZ) trades at $20.87, up 7.36% today, amid strong analyst support with 19 buy ratings and a $35.88 consensus price target. The stock shows bearish technical signals with resistance at $21, while fundamentals reveal significant losses (-$288.62M net income in 2025) despite revenue growth to $319M. Recent AMD partnership for 2.5GW data center capacity signals strategic pivot to AI infrastructure.
Outlook balances high growth potential from AI contracts against substantial cash burn and negative margins. Key risks include execution of expansion plans and profitability timeline, but institutional interest and analyst optimism suggest upside if operational targets are met.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →